An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura
- 15 May 2019
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Hematology
- Vol. 12 (6), 383-395
- https://doi.org/10.1080/17474086.2019.1611423
Abstract
Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, consumption thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, the specific von Willebrand factor (VWF)-cleaving protease. Areas covered: VWF/ADAMTS13 interaction is specific, and ADAMTS13 conformation has been elucidated recently. ADAMTS13 deficiency is congenital or acquired. Several targets are used in TTP treatment. Expert opinion: Differential diagnosis of TTP may be challenging and ADAMTS13 investigations are needed. ADAMTS13 conformation could be a promising parameter for TTP diagnosis and prognosis in the coming years. Plasma therapy remains the first-line treatment of the acute phase of TTP. Additional curative and preemptive rituximab are used in acquired TTP. Clinical trials dedicated to innovative drugs are promising.Keywords
This publication has 80 references indexed in Scilit:
- Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2013
- Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registryHamostaseologie, 2013
- ON THE VERSATILITY OF VON WILLEBRAND FACTORMediterranean Journal of Hematology and Infectious Diseases, 2013
- Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factorBlood, 2011
- Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in JapanJournal of Thrombosis and Haemostasis, 2011
- Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domainHaematologica, 2011
- N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and miceJCI Insight, 2011
- Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center ExperiencePLOS ONE, 2010
- Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndromeBlood, 2003
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982